EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

Xeris Biopharma Holdings, Inc. (XERS) had EBITDA of $20.84M for the most recently reported fiscal quarter, ending 2025-12-31.

Quarterly Annual

Figures for fiscal quarter ending 2025-12-31

Income Statement Financials
Revenue	$85.81M
Net Income	$11.08M
Cost of Goods Sold	$10.95M
Gross Profit	$74.86M
Operating Expenses	$69.03M
Operating Income	$16.77M
Non-Operating Income/Expense	$-5.69M
Pre-Tax Income	$11.08M
Normalized Pre-Tax Income	$11.08M
Income after Taxes	$11.08M
Income from Continuous Operations	$11.08M
Consolidated Net Income/Loss	$11.08M
Normalized Income after Taxes	$11.08M
EBIT	$16.77M
EBITDA	$20.84M
Weighted-Average Shares Outstanding (Basic)	160.43M
Weighted-Average Shares Outstanding (Diluted)	172.74M
Earnings per Share (EPS) (Basic)	$0.07
Earnings per Share (EPS) (Diluted)	$0.07
Balance Sheet Financials
Current Assets	$240.31M
Property, Plant, and Equipment	$4.95M
Long-Term Assets	$143.21M
Total Assets	$383.53M
Current Liabilities	$109.57M
Long-Term Debt	$220.34M
Long-Term Liabilities	$260.26M
Total Liabilities	$369.84M
Common Equity	$13.69M
Tangible Shareholders Equity	$-97.25M
Shareholders Equity	$13.69M
Common Shares Outstanding	166.22M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$28.63M
Cash Flow from Investing Activities	$-0.70M
Cash Flow from Financial Activities	$11.39M
Beginning Cash	$75.74M
End Cash	$115.06M
Increase/Decrease in Cash	$39.32M
Stock-Based Compensation	$22.37M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	2.19
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.94
Debt to Equity Ratio	16.10
Gross Margin	87.24%
Operating Margin	19.55%
EBIT Margin	19.55%
EBITDA Margin	--
Pre-Tax Profit Margin	12.91%
Profit Margin	12.91%
Free Cash Flow	$27.93M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.22
Inventory Turnover	0.16
Receiveable Turnover	1.68
Days Sales in Receivables	53.54
Return on Equity	80.95%
Return on Tangible Equity	-11.39%
Return on Assets	2.89%
Return on Investments	4.74%
Book Value Per Share	$0.08
Free Cash Flow per Share	$0.16
Operating Cash Flow per Share	$0.17

Data from Zacks Investment Research, Inc.